Cargando…
Update on GPCR-based targets for the development of novel antidepressants
Traditional antidepressants largely interfere with monoaminergic transport or degradation systems, taking several weeks to have their therapeutic actions. Moreover, a large proportion of depressed patients are resistant to these therapies. Several atypical antidepressants have been developed which i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960420/ https://www.ncbi.nlm.nih.gov/pubmed/33589739 http://dx.doi.org/10.1038/s41380-021-01040-1 |
_version_ | 1784677378447900672 |
---|---|
author | Mantas, Ioannis Saarinen, Marcus Xu, Zhi-Qing David Svenningsson, Per |
author_facet | Mantas, Ioannis Saarinen, Marcus Xu, Zhi-Qing David Svenningsson, Per |
author_sort | Mantas, Ioannis |
collection | PubMed |
description | Traditional antidepressants largely interfere with monoaminergic transport or degradation systems, taking several weeks to have their therapeutic actions. Moreover, a large proportion of depressed patients are resistant to these therapies. Several atypical antidepressants have been developed which interact with G protein coupled receptors (GPCRs) instead, as direct targeting of receptors may achieve more efficacious and faster antidepressant actions. The focus of this review is to provide an update on how distinct GPCRs mediate antidepressant actions and discuss recent insights into how GPCRs regulate the pathophysiology of Major Depressive Disorder (MDD). We also discuss the therapeutic potential of novel GPCR targets, which are appealing due to their ligand selectivity, expression pattern, or pharmacological profiles. Finally, we highlight recent advances in understanding GPCR pharmacology and structure, and how they may provide new avenues for drug development. |
format | Online Article Text |
id | pubmed-8960420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-89604202022-04-07 Update on GPCR-based targets for the development of novel antidepressants Mantas, Ioannis Saarinen, Marcus Xu, Zhi-Qing David Svenningsson, Per Mol Psychiatry Expert Review Traditional antidepressants largely interfere with monoaminergic transport or degradation systems, taking several weeks to have their therapeutic actions. Moreover, a large proportion of depressed patients are resistant to these therapies. Several atypical antidepressants have been developed which interact with G protein coupled receptors (GPCRs) instead, as direct targeting of receptors may achieve more efficacious and faster antidepressant actions. The focus of this review is to provide an update on how distinct GPCRs mediate antidepressant actions and discuss recent insights into how GPCRs regulate the pathophysiology of Major Depressive Disorder (MDD). We also discuss the therapeutic potential of novel GPCR targets, which are appealing due to their ligand selectivity, expression pattern, or pharmacological profiles. Finally, we highlight recent advances in understanding GPCR pharmacology and structure, and how they may provide new avenues for drug development. Nature Publishing Group UK 2021-02-15 2022 /pmc/articles/PMC8960420/ /pubmed/33589739 http://dx.doi.org/10.1038/s41380-021-01040-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Expert Review Mantas, Ioannis Saarinen, Marcus Xu, Zhi-Qing David Svenningsson, Per Update on GPCR-based targets for the development of novel antidepressants |
title | Update on GPCR-based targets for the development of novel antidepressants |
title_full | Update on GPCR-based targets for the development of novel antidepressants |
title_fullStr | Update on GPCR-based targets for the development of novel antidepressants |
title_full_unstemmed | Update on GPCR-based targets for the development of novel antidepressants |
title_short | Update on GPCR-based targets for the development of novel antidepressants |
title_sort | update on gpcr-based targets for the development of novel antidepressants |
topic | Expert Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960420/ https://www.ncbi.nlm.nih.gov/pubmed/33589739 http://dx.doi.org/10.1038/s41380-021-01040-1 |
work_keys_str_mv | AT mantasioannis updateongpcrbasedtargetsforthedevelopmentofnovelantidepressants AT saarinenmarcus updateongpcrbasedtargetsforthedevelopmentofnovelantidepressants AT xuzhiqingdavid updateongpcrbasedtargetsforthedevelopmentofnovelantidepressants AT svenningssonper updateongpcrbasedtargetsforthedevelopmentofnovelantidepressants |